Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2545104 | 0.90 | POLB (0.42) | POLBTDP1ALDH1A1L3MBTL1APEX1 | |
| SCHEMBL6125172 | 0.79 | ALDH1A1 (0.50) | POLBTDP1ALDH1A1L3MBTL1RECQL | |
| SCHEMBL2386798 | 0.79 | ALDH1A1 (0.50) | POLBTDP1ALDH1A1L3MBTL1RECQL | |
| SCHEMBL14338369 | 0.79 | ALDH1A1 (0.50) | POLBTDP1ALDH1A1L3MBTL1RECQL | |
| SCHEMBL6127457 | 0.73 | TDP1 (0.44) | POLBTDP1ALDH1A1L3MBTL1APEX1 | |
| SCHEMBL3199039 | 0.73 | TDP1 (0.44) | POLBTDP1ALDH1A1L3MBTL1APEX1 | |
| SCHEMBL18723992 | 0.73 | TDP1 (0.44) | POLBTDP1ALDH1A1L3MBTL1APEX1 | |
| SCHEMBL16199087 | 0.73 | TDP1 (0.44) | POLBTDP1ALDH1A1L3MBTL1APEX1 | |
| SCHEMBL9528093 | 0.73 | POLB (0.34) | POLBTDP1ALDH1A1L3MBTL1APEX1 | |
| SCHEMBL3199047 | 0.73 | TDP1 (0.44) | POLBTDP1ALDH1A1L3MBTL1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350021-B1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-8314253-B2 | Bridged tetrahydronaphthalene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | CACNA1E, CACNA1B, CACNB1 | POLB 3291/4885TDP1 2859/4885ALDH1A1 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.